Nicotinamide → (2R,3S,4R,5R)-2,3,4,5,6-pentahydroxyhexanal

HRID 1486359

Reaktionsgleichung

Reaktionsgleichung von HRID 1486359
CC(C)=CO[Si](C)(C)C.C[C@H]1C2(C(C)=C3C(C4C(C3)C3(C)C(CC(CC3)=O)=CC4)CC2)O[C@@H]2CC(C)CN(CCNC(CCCCCNC(CCC3C=CC=CC=3)=O)=O)C12.CC1CCCC(C)(C)C=1/C=C/C(/C)=C/C=C/C(/C)=C/C(O)=O.C[C@H](NC(CC1C=C(F)C=C(F)C=1)=O)C(N[C@H](C(OC(C)(C)C)=O)C1C=CC=CC=1)=O.CC[C@@H]([C@H](NC([C@@H](NC([C@@H](NC([C@@H](NC([C@@H](NC([C@@H](NC([C@@H](NC([C@@H](NC([C@@H](NC([C@@H](NC([C@@H](NC([C@@H](NC([C@@H](NC([C@@H](NC([C@@H](NC([C@@H](NC([C@@H](NC([C@@H](NC([C@@H](NC(CNC([C@@H](NC(CNC([C@@H](N)CC1NC=NC=1)=O)=O)CCC(O)=O)=O)=O)[C@H](O)C)=O)CC1C=CC=CC=1)=O)[C@H](O)C)=O)CO)=O)CC(O)=O)=O)CC(C)C)=O)CO)=O)CCCCN)=O)CCC(N)=O)=O)CCSC)=O)CCC(O)=O)=O)CCC(O)=O)=O)CCC(O)=O)=O)C)=O)C(C)C)=O)CCCNC(N)=N)=O)CC(C)C)=O)CC1C=CC=CC=1)=O)C(N[C@H](C(N[C@H](C(N[C@H](C(N[C@H](C(N[C@H](C(NCC(NCC(N1[C@H](C(N[C@H](C(N[C@H](C(NCC(N[C@H](C(N2[C@H](C(N3[C@H](C(N4[C@H](C(N[C@H](C(N)=O)CO)=O)CCC4)=O)CCC3)=O)CCC2)=O)C)=O)=O)CO)=O)CO)=O)CCC1)=O)=O)=O)CC(N[C@@H]1O[C@H](CO)[C@@H]([O:175][C@@H:176]2[O:181][C@H:180]([CH2:182][O:183][C@@]3(C(O)=O)O[C@@H](C[C@H](O)[C@H](O)CO)[C@H](NC(C)=O)[C@@H](O)C3)[C@H:179]([OH:205])[C@H:178]([OH:206])[C@H:177]2[OH:207])[C@H](O)[C@H]1NC(C)=O)=O)=O)CCCCN)=O)CC(C)C)=O)CC1C2C=CC=CC=2NC=1)=O)CCC(O)=O)=O)C.C(N)(=O)C1C=CC=NC=1>>[O:175]=[CH:176][C@@H:177]([C@H:178]([C@@H:179]([C@@H:180]([CH2:182][OH:183])[OH:181])[OH:205])[OH:206])[OH:207]

Komponenten

7

Edukt 6

HCID 936Nicotinamide2×HCID 99685Isobutyraldehyde trimethylsilyl enol ether3×HCID 444795Retinoic AcidHCID 5311272Dapt2×HCID 16760383N-[2-[(3'R,7'aR)-3',6',10,11b-tetramethyl-3-oxospiro[1,2,4,6,6a,6b,7,8,11,11a-decahydrobenzo[a]fluorene-9,2'-3,3a,5,6,7,7a-hexahydrofuro[3,2-b]pyridine]-4'-yl]ethyl]-6-(3-phenylpropanoylamino)hexanamide2×HCID 49862879CID 498628792×

Produkt 1

HCID 107526(2R,3S,4R,5R)-2,3,4,5,6-pentahydroxyhexanal

Versuchsvorschrift

Cells were reprogrammed according to Example 11, and were then cultured in DMEM/F12, 100 ng/ml activin A, 25 ng/ml Wnt3a, 0.01% recombinant HSA, 1×ITSE for 1 day, followed by DMEM/F12, 100 ng/ml activin A, 0.01% recombinant HSA, 1×ITSE for 2 days, followed by DMEM/F12, 50 ng/ml FGF10, 0.25 μM KAAD-cyclopamine, 0.01% recombinant HSA, 1×ITSE for 3 days, followed by DMEM/F12, 1% B27, 2 μM all-trans retinoic acid, 50 ng/ml FGF10, 0.25 μM KAAD-cyclopamine for 4 days, followed by DMEM/F12, 1% B27, 1 μM γ-secretase inhibitor DAPT, 50 ng/ml exendin-4, 10 nM betacellulin, 10 mM nicotinamide for 2 days, followed by DMEM/F12, 50 mg/L ascorbic-acid-2-phosphate, 1% B27, 1 μM γ-secretase inhibitor DAPT, 50 ng/ml exendin-4, 50 ng/ml IGF-1, 50 ng/ml HGF, 10 nM betacellulin, 10 mM nicotinamide for 6 days to generate glucose-responsive insulin-producing cells (FIG. 5A). The resulting cells can be used in vitro or in vivo for screening bioactive molecules for the study of diabetes or for the development of therapeutics for diabetes.

Aufarbeitung

  1. customfor 1 day
  2. customfor 2 days

Quellen und Nachweise

ORD-Eintrag
ord-b37f66fc11ba448e86674f1bc8ce2d4a
Quelldatensatz
uspto-grants-2016_08
Patentnummer
US09422577B2

Verknüpfte Notizen

Wird geladen…